Announced Date: 2020-06-01 (June 1, 2020)
Asset Name: JAB-3068 and JAB-3312
Licensor (Seller): Jacobio Pharmaceuticals (China)
Licensee (Buyer): AbbVie
.
Asset Modality: Small Molecule
Asset Target: SHP2 inhibitors
Potential Indication: solid tumor
Stage until the deal: early clinical stage
.
Scope of Authority:
AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses. Upon completion, AbbVie will assume global development and commercialization responsibilities. Jacobio has an option, exercisable before the initiation of registrational trials, to exclusively develop and commercialize the SHP2 program in mainland China, Hong Kong, and Macau.
.
Payment Detail:
Jacobio will receive
Upfront payment of $45 million,
Development, commercial milestone payments up to $ 855 million.
Tiered royalties on net sales.
.
Link:
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors – Jun 1, 2020
.
Note:
Chinese Name of “Jacobio“，加科思
